On ECHEMI
Home > Drugs > Spinal muscular atrophy
Spinal muscular atrophy
Spinal muscular atrophy (SMA) refers to a type of disease that causes muscle weakness and atrophy due to degeneration of the anterior horn cells of the spinal cord. It was first reported by Werdnig (1891) and Hoffmann (1893), so it is also called Werdnig-Hoffmann disease. According to the age of onset and the degree of lesions, this disease can be divided into 4 types: Types I to III are called childhood SMA, which is an autosomal recessive genetic disease with a population incidence of 1/6000 to 1/10000. It is the most common lethal genetic disease in infancy. SMA that starts in children over 20 to 30 years old is classified as type IV, which can be inherited in different ways such as autosomal recessive, dominant and X-linked recessive, and its population incidence is about 0.32/10000. Due to various clinical and genetic characteristics, it is generally believed that this disease should be separated from motor neuron diseases and become a group of independent diseases.
  • Site of disease:

    spinal cord
  • Infectious :

    Not contagious
  • Frequent population:

    Common in infants and children
  • Related symptoms:

    Weakness Joint deformity Sensory impairment Loss of tendon reflexes Difficulty swallowing
  • Concurrent disease:

Related Drugs
Jingtong Granules
Manufacturer:

Sichuan Defeng Pharmaceutical Co., Ltd.

Myo-aminopeptide injection
Indication: Paralysis caused by cerebrovascular accident; muscle atrophy caused by peripheral nervous system diseases; neurasthenia syndrome, etc.
Manufacturer:

Jilin Aodong--Taonan Pharnalentical Company Ltd

Myo-aminopeptide injection
Indication: Paralysis caused by cerebrovascular accident; muscle atrophy caused by peripheral nervous system diseases; neurasthenia syndrome, etc.
Manufacturer:

Jilin Aodong--Taonan Pharnalentical Company Ltd

EVRYSDI- risdiplam_powder, for solution
Indication: EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Manufacturer:

EVRYSDI- risdiplam_tablet

Related Ingredients
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.